See the DrugPatentWatch profile for Qulipta
Qulipta (atogepant) is a medication used to prevent migraine headaches. Like all medications, it can cause side effects.
What are the most common side effects reported for Qulipta?
The most frequently reported side effects of Qulipta include upper respiratory tract infection, nausea, and diarrhea [1].
Are there any serious side effects associated with Qulipta?
While less common, some patients may experience more serious side effects. These can include allergic reactions [1]. Symptoms of an allergic reaction may involve rash, itching, or swelling, particularly of the face, tongue, or throat, and severe dizziness or trouble breathing [1].
What should I do if I experience side effects from Qulipta?
If you experience any side effects, especially those that are severe or persistent, you should contact your doctor [1].
What is the mechanism of action for Qulipta?
Qulipta works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that plays a role in migraine pain [2]. By inhibiting CGRP, Qulipta helps to prevent migraine attacks [2].
How does Qulipta compare to other migraine prevention medications?
Qulipta is a CGRP inhibitor, a class of drugs that has emerged as a significant option for migraine prevention. Other CGRP inhibitors are available both as oral medications and injectable treatments [3]. The choice of medication often depends on individual patient needs, response, and preferences [3].
When does the patent for Qulipta expire?
Information regarding the patent expiration for Qulipta can be found on specialized drug patent tracking websites [4]. For example, DrugPatentWatch.com tracks patent information for numerous medications, including Qulipta [4].
Who manufactures Qulipta?
Qulipta is manufactured by AbbVie [1].
*
**Sources:
[1] https://www.qulipta.com/migraine-medication/side-effects
[2] https://www.qulipta.com/migraine-medication
[3] https://www.neurologyadvisor.com/home/decision-support-in-neurology/headache/cgrp-antagonists-for-migraine-prophylaxis/
[4] https://www.drugpatentwatch.com/